Research26-A-10988-ACC BLUNTED HEART RATE RESPONSE TO REGADENOSON IS ASSOCIATED WITH HIGH RISK BEYOND PET QUANTITATIVE MYOCARDIAL BLOOD FLOW
ResearchPeripheral Artery Disease, Coronary Microvascular Dysfunction, and Adverse Cardiovascular Events
ResearchPrognostic Value of Myocardial Flow Reserve in Patients with Prior CABG or PCI and Normal Perfusion
Jan 15, 2026Journal ArticleA Road Map to Understanding Cardiovascular Disease in Diabetes: From the AHA Strategically Focused Research Network in Cardiometabolic Health and Type 2 Diabetes.Written by 1 Roon author & 18 others Via The American Heart Association Journals
ResearchComparative risk assessment of cardiovascular and kidney outcomes in patients with type 2 diabetes using cystatin C and creatinine in DECLARE-TIMI 58
ResearchA Multicenter Randomized Clinical Trial of Dapagliflozin in Patients Receiving Chronic Dialysis (The DARE-ESKD-2 Trial)
ResearchDOTA-based perfusion imaging in hybrid positron emission tomography/magnetic resonance: Promise, limits, and the importance of tracer kinetics
Mar 30, 2026Journal ArticleEffect of APOC3 Inhibition With Olezarsen on Coronary Atherosclerosis: Essence-TIMI 73b Imaging Study.Written by 1 Roon author & 24 others Via The American Heart Association Journals
ResearchEffects of Dapagliflozin on Cardiovascular Outcomes in Patients With Type 2 Diabetes at Risk of Liver Fibrosis
ResearchBlunted heart rate response to regadenoson predicts cardiovascular risk beyond quantitative positron emission tomography myocardial blood flow
ResearchBeyond the apnea-hypopnea index: Precision cardiovascular risk stratification in obstructive sleep apnea
ResearchSacubitril/Valsartan versus Enalapril or Losartan at Maximum Doses in Heart Failure with Reduced Ejection Fraction: Real-World Data
ResearchLow-dose CT as a diagnostic clue: Unmasking anemia as a cause of reduced myocardial flow reserve on PET/CT
